Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PTN vs JAGX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PTN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–3 Matrix Metrics)

PTN Overall Winner 6-Pillar Tally: PTN 3 – 2 JAGX (1 Tie) Matrix Metrics: PTN 6 – 3 JAGX

As of Nov 16, 2026, Palatin Technologies, Inc. (PTN) is the stronger overall head-to-head candidate over Jaguar Health, Inc. (JAGX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, R&D & Supply-Chain Moat). PTN carries a Unified Composite Score of 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin), whereas JAGX carries 54.5/100 (HOLD) at $0.39 (N/M Forward P/E, -90.2% operating margin).

  • Composite vs. Pillar Nuance: While JAGX currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. PTN 31.5/100 SELL), PTN captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-65.7% vs. -90.2% operating margin) and revenue trajectory (-80.1% vs. -58.9% YoY).
  • Technical & Structure Timing Caution: PTN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9); meanwhile JAGX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PTN vs JAGX
PTN US Equity Head-to-Head Winner
Palatin Technologies, Inc.
Pharmaceutical Preparations
$6.12
-1.69% 1D
Market Cap $11.1M
TTM Revenue $13M
Forward P/E 42.9x
Beta / 30D Vol 0.87β · 106% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 15.0 Fund 30.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.5%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $5.72 · SMA50: $8.07
JAGX NASDAQ
Jaguar Health, Inc.
Pharmaceutical Preparations
$0.39
-7.74% 1D
Market Cap $5.6M
TTM Revenue $28M
Forward P/E N/M
Beta / 30D Vol 30.19β · 228% Vol
Unified Composite Score
54.5 / 100 HOLD
Tech 60.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.8 · SMA20: $1.24 · SMA50: $3.31

6-Pillar Scorecard Institutional Category Breakdown (PTN 3 – 2 JAGX)

Columns: Metric · PTN · JAGX
1. Valuation Multiples PTN
Forward P/E 42.9x N/M
Trailing P/E 42.9x N/M
PEG Ratio 1.62x N/M
EV / Revenue 0.1x 0.7x
2. Growth & Scale JAGX
Revenue Growth (YoY) -80.1% -58.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $13M $28M
Market Cap $11.1M $5.6M
3. Profitability & Quality PTN
Gross Margin 6.2% 82.3%
Operating Margin -65.7% -90.2%
Net Profit Margin -63.5% -130.8%
Return on Equity (ROE) -877.5% -548.8%
4. Balance Sheet & Cash Flow JAGX
Cash Generation (TTM) -$15M -$6.7M
Cash Flow Margin -113.6% -24.2%
Net Cash / Leverage $9.9M Net Cash $15M Net Debt (2.77x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat PTN
OpEx & R&D Intensity 71.9% of Rev ($9.5M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PTN (6) vs JAGX (3)
Institutional Metric PTN JAGX Criterion Row Edge
Market Capitalization
Scale
$11.1M $5.6M Larger Scale Tie
Trailing P/E Ratio
Valuation
42.9x N/M Lower Multiple PTN
Forward P/E Ratio
Valuation
42.9x N/M Lower Multiple PTN
Revenue Growth (YoY)
Growth
-80.1% -58.9% Higher Growth JAGX
Operating Margin (TTM)
Profitability
-65.7% -90.2% Higher Margin PTN
Net Profit Margin
Profitability
-63.5% -130.8% Higher Margin PTN
Return on Equity (ROE)
Capital Efficiency
-877.5% -548.8% Higher ROE JAGX
52-Week Range Position
Momentum
6% ($5–$31) 0% ($0–$42) Stronger Trend PTN
Beta / 30D Volatility
Risk Regime
0.87β · 106% Vol 30.19β · 228% Vol Lower Realized Risk PTN
Unified Institutional Score
Composite Signal
31.5 / 100 (SELL) 54.5 / 100 (HOLD) Higher Composite JAGX
Trailing 12M Revenue (USD)
Operating Scale
$13M $28M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
6.2% 82.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.62x PEG · 0.1x EV/Rev N/M PEG · 0.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$15M ($9.9M Net Cash) -$6.7M ($15M Net Debt (2.77x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PTN +90.78 pp
PTN: +1.74% · JAGX: -89.04%
3M Horizon PTN +18.71 pp
PTN: -41.72% · JAGX: -60.43%
6M Horizon PTN +29.75 pp
PTN: -59.81% · JAGX: -89.56%
1Y Horizon PTN +33.98 pp
PTN: -43.29% · JAGX: -77.27%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PTN Revenue JAGX Revenue PTN Op. Margin JAGX Op. Margin Margin Leader
FY2019 $60M $10M 59.3% -501.3% PTN
FY2020 $0M $10M -20007.6% -283.9% JAGX
FY2021 N/A $0M N/A -939.1% JAGX
FY2022 $0M $10M -2491.6% -287.8% JAGX
FY2023 $0M $10M -668.7% -351.3% JAGX
FY2024 $0M $10M -501.0% -263.8% JAGX
FY2025 N/A $10M N/A -398.8% JAGX
FY2026 $10M N/A -65.7% N/A PTN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PTN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PTN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
JAGX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact JAGX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PTN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $11.1M market capitalization and -65.7% operating margin.
OpEx & R&D Reinvestment 71.9% of Rev ($9.5M)
90D Engineering Disclosures 0 Published
JAGX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $5.6M market capitalization and -90.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PTN vs JAGX Key Questions & Quantitative Answers

As of Nov 16, 2026, Palatin Technologies, Inc. (PTN) is the stronger overall head-to-head candidate over Jaguar Health, Inc. (JAGX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, R&D & Supply-Chain Moat). PTN carries a Unified Composite Score of 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin), whereas JAGX carries 54.5/100 (HOLD) at $0.39 (N/M Forward P/E, -90.2% operating margin). Composite vs. Pillar Nuance: While JAGX currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. PTN 31.5/100 SELL), PTN captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-65.7% vs. -90.2% operating margin) and revenue trajectory (-80.1% vs. -58.9% YoY). Technical & Structure Timing Caution: PTN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9); meanwhile JAGX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

JAGX leads the Growth & Scale pillar: PTN posts -80.1% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (6.2% gross margin, -65.7% operating margin), compared with JAGX at -58.9% YoY revenue growth and +0.0% YoY earnings growth on $28M TTM revenue (82.3% gross margin, -90.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), PTN cumulative revenue shifted -83.3% while JAGX shifted +0.0%. In operating R&D and SG&A reinvestment, PTN deploys 71.9% of Rev ($9.5M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for JAGX.

PTN screens cheaper on headline valuation multiples. PTN trades at 42.9x Forward P/E, 42.9x Trailing P/E, 1.62x PEG, and 0.1x EV/Revenue (-113.6% FCF margin), whereas JAGX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-24.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PTN (-877.5% ROE) versus JAGX (-548.8% ROE) capital efficiency.

In options market volatility and institutional positioning, PTN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 106% Vol realized risk). By comparison, JAGX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (30.19β · 228% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.